Rare Disease Patient Registry: Coordination of Rare Diseases at Sanford (CoRDS)
The purpose of this registry is to create a central resource that connects scientists conducting rare disease research studies with affected individuals interested in participating in research.
Disorders of Unknown Prevalence
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Target Follow-Up Duration:||100 Years|
|Official Title:||Coordination of Rare Diseases at Sanford|
- To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases. [ Time Frame: 100 years ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
Biospecimen collection capability anticipated in 2014.
|Study Start Date:||July 2010|
|Estimated Primary Completion Date:||December 2100 (Final data collection date for primary outcome measure)|
CoRDS collects contact, sociodemographic and health information about participants. This information is entered into CoRDS and linked to a unique coded identifier. Below are some examples of information requested on the Questionnaire that will be entered into CoRDS:
- Contact information: Name, Mailing Address, Phone Number, Email Address
- Sociodemographic information: Date of Birth, Place of Birth, Sex, Gender, Ethnicity
- Health information: Family History, Information related to Diagnosis
De-identified information in CoRDS will be made available to researchers, if they have obtained approval for their research project from (1) the Institutional Review Board (IRB) at the researcher's institution and (2) a panel of experts led by Dr. David A. Pearce.
A subset of de-identified information collected from each profile may be shared with certain other databases. This is done in order to help improve understanding of rare diseases, to avoid the duplication of efforts and to collaborate with existing research efforts and organizations dedicated to rare diseases.
Participants may elect to have their information shared with patient advocacy groups (PAGs) representing individuals with rare or uncommon diseases who have partnered with CoRDS. The PAG will sign an agreement stating that they will not use the information for Research purposes. Dr. David A. Pearce and CoRDS personnel will not be held responsible for the use of information by the PAG.
The CoRDS Registry will not be paid by Researchers, Other Patient Registries or Patient Advocacy Groups (PAGs) for access to information in CoRDS.
If a parent/LAR consents on behalf of a minor, CoRDS will contact the participant when he or she reaches the age of 18 in order to obtain consent. If this consent is not obtained in a timely manner, the participant will be withdrawn from CoRDS.
CoRDS contacts participants annually to confirm continued interest in participation in CoRDS, and to request that participants update the information they have provided.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01793168
|Contact: Liz Donohueemail@example.com|
|United States, South Dakota|
|Sioux Falls, South Dakota, United States, 57104|
|Principal Investigator: David A Pearce, PhD|
|Principal Investigator:||David A Pearce, PhD||Sanford Health|